Integra LifeSciences (NASDAQ:IART) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Integra LifeSciences (NASDAQ:IART) announced its quarterly earnings data on Monday. The life sciences company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.01, Briefing.com reports. Integra LifeSciences had a return on equity of 14.27% and a net margin of 2.63%. The company had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. During the same quarter last year, the firm posted $0.71 EPS. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis.

Integra LifeSciences Trading Down 1.1 %

IART traded down $0.28 during mid-day trading on Tuesday, hitting $25.14. 602,631 shares of the stock were exchanged, compared to its average volume of 1,119,833. The firm’s fifty day moving average is $29.72 and its two-hundred day moving average is $33.65. Integra LifeSciences has a 1-year low of $22.36 and a 1-year high of $46.09. The company has a market cap of $1.98 billion, a PE ratio of 50.84, a PEG ratio of 1.14 and a beta of 1.11. The company has a current ratio of 4.68, a quick ratio of 3.35 and a debt-to-equity ratio of 1.15.

Insider Buying and Selling at Integra LifeSciences

In other Integra LifeSciences news, Chairman Stuart Essig acquired 52,641 shares of the stock in a transaction dated Thursday, May 23rd. The stock was acquired at an average price of $28.49 per share, with a total value of $1,499,742.09. Following the completion of the purchase, the chairman now owns 487,922 shares in the company, valued at approximately $13,900,897.78. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on IART shares. StockNews.com downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Wells Fargo & Company cut Integra LifeSciences from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $45.00 to $25.00 in a report on Tuesday, May 7th. BTIG Research lowered Integra LifeSciences from a “neutral” rating to a “sell” rating and set a $22.00 price target for the company. in a research report on Tuesday. Bank of America cut their price target on Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating for the company in a report on Tuesday, May 7th. Finally, Morgan Stanley boosted their price objective on Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research note on Monday, July 15th. Four research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $29.88.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.